<DOC>
	<DOCNO>NCT01698333</DOCNO>
	<brief_summary>Adrenal suppression effect corticosteroids among important safety concern group product . This study design determine adrenal effect investigational formulation 122-0551 characterize steady state pharmacokinetics formulation .</brief_summary>
	<brief_title>Pharmacokinetics 122-0551 Its Effects Adrenal Suppression</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject clinical diagnosis stable plaque psoriasis Subject spontaneously improve rapidly deteriorate plaque psoriasis Subject guttate , pustular , erythrodermic nonplaque form psoriasis Subject use phototherapy , photochemotherapy systemic psoriasis therapy within 30 day prior initiation treatment Subject use systemic corticosteroid topical , inhaled , intranasal corticosteroid within 30 day 14 day , respectively , prior study screen Subject prolong exposure natural artificial source ultraviolet radiation within 30 day prior initiation treatment Subject use topical psoriatic therapy include tar , anthralin , retinoids , vitamin D analog ( e.g. , DovonexÂ® ) within 14 day prior initiation treatment Subject use emollients/moisturizers area treat within one day prior initiation treatment Subject currently use lithium Plaquenil ( hydroxychloroquine ) Subject currently use betablocking medication ( e.g. , propanolol ) angiotensin convert enzyme ( ACE ) inhibitor ( e.g. , lisinopril ) dose stabilize Subject pregnant , nurse plan pregnancy study period Subject currently enrol investigational drug , biologic device study Subject receive investigational drug , biologic investigational device within 30 day prior study start Subject previously enrol study treat test article Subject irregular sleep schedule work night shift</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>122-0551</keyword>
	<keyword>steroid</keyword>
	<keyword>HPA</keyword>
</DOC>